- Home
- CERO vs TCRT Comparison
CERO vs TCRT Comparison
Compare CERO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- TCRT
- Stock Information
- Founded
- CERO 2017
- TCRT 1998
- Country
- CERO United States
- TCRT United States
- Employees
- CERO N/A
- TCRT N/A
- Industry
- CERO
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- TCRT Health Care
- Exchange
- CERO Nasdaq
- TCRT Nasdaq
- Market Cap
- CERO 6.1M
- TCRT 7.0M
- IPO Year
- CERO N/A
- TCRT N/A
- Fundamental
- Price
- CERO $1.99
- TCRT $3.07
- Analyst Decision
- CERO Strong Buy
- TCRT
- Analyst Count
- CERO 2
- TCRT 0
- Target Price
- CERO $45.00
- TCRT N/A
- AVG Volume (30 Days)
- CERO 291.2K
- TCRT 1.3M
- Earning Date
- CERO 11-18-2025
- TCRT 11-13-2025
- Dividend Yield
- CERO N/A
- TCRT N/A
- EPS Growth
- CERO N/A
- TCRT N/A
- EPS
- CERO N/A
- TCRT N/A
- Revenue
- CERO N/A
- TCRT $6,000.00
- Revenue This Year
- CERO N/A
- TCRT $5,680,500.00
- Revenue Next Year
- CERO N/A
- TCRT N/A
- P/E Ratio
- CERO N/A
- TCRT N/A
- Revenue Growth
- CERO N/A
- TCRT N/A
- 52 Week Low
- CERO $1.93
- TCRT $1.31
- 52 Week High
- CERO $895.40
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- CERO 14.42
- TCRT 53.91
- Support Level
- CERO $5.18
- TCRT $3.02
- Resistance Level
- CERO $5.66
- TCRT $3.59
- Average True Range (ATR)
- CERO 0.42
- TCRT 0.35
- MACD
- CERO -0.26
- TCRT 0.01
- Stochastic Oscillator
- CERO 1.61
- TCRT 30.88
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.